{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:44:49Z","timestamp":1741067089967,"version":"3.38.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jclinepi.2024.111589","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T02:01:29Z","timestamp":1730772089000},"page":"111589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Statistical noise in PD-(L)1 inhibitor trials: unraveling the durable-responder effect"],"prefix":"10.1016","volume":"177","author":[{"given":"Michael","family":"Coory","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan J.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2022","series-title":"In the eye of the storm: PD-(L)1 inhibitors weathering turbulence","author":"Gores","key":"10.1016\/j.jclinepi.2024.111589_bib1"},{"key":"10.1016\/j.jclinepi.2024.111589_bib2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jclinepi.2024.111589_bib3","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3390\/jcm8101534","article-title":"The evolving landscape of biomarkers for anti-PD-1 or anti-PD-L1 therapy","volume":"8","author":"Tunger","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jclinepi.2024.111589_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-022-06665-6","article-title":"Clinical trials of immunotherapy in triple-negative breast cancer","volume":"195","author":"Howard","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jclinepi.2024.111589_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.jclinepi.2024.111589_bib6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2021.02.004","article-title":"Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy","volume":"32","author":"Smyth","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jclinepi.2024.111589_bib8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2024.111589_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jclinepi.2024.111589_bib10","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2024.111589_bib11","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2024.111589_bib12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111589_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jclinepi.2024.111589_bib14","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jclinepi.2024.111589_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111589_bib16","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2024.111589_bib17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","article-title":"Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study","volume":"34","author":"Psyrri","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jclinepi.2024.111589_bib7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1370\/afm.848","article-title":"Understanding uncertainty","volume":"6","author":"Spiegelhalter","year":"2008","journal-title":"Annals Family Med"},{"key":"10.1016\/j.jclinepi.2024.111589_bib18","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/sim.8086","article-title":"Using simulation studies to evaluate statistical methods","volume":"38","author":"Morris","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.jclinepi.2024.111589_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/sim.4780010204","article-title":"Tables of the number of patients required in clinical trials using the logrank test","volume":"1","author":"Freedman","year":"1982","journal-title":"Stat Med"},{"key":"10.1016\/j.jclinepi.2024.111589_bib20","doi-asserted-by":"crossref","first-page":"e2227211","DOI":"10.1001\/jamanetworkopen.2022.27211","article-title":"Analysis of cancer survival associated with immune checkpoint inhibitors after statistical adjustment: a systematic review and meta-analyses","volume":"5","author":"Lin","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jclinepi.2024.111589_bib21","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111589_bib22","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jamaoncol.2022.2666","article-title":"Log-rank test vs MaxCombo and difference in restricted mean survival time tests for comparing survival under nonproportional hazards in immuno-oncology trials: a systematic review and meta-analysis","volume":"8","author":"Mukhopadhyay","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jclinepi.2024.111589_bib23","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1200\/JCO.19.01681","article-title":"Methods for accommodating nonproportional hazards in clinical trials: ready for the primary analysis?","volume":"37","author":"Freidlin","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2024.111589_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrn3475","article-title":"Power failure: why small sample size undermines the reliability of neuroscience","volume":"14","author":"Button","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.jclinepi.2024.111589_bib25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10940-017-9374-5","article-title":"Type M error might explain Weisburd\u2019s paradox","volume":"36","author":"Gelman","year":"2020","journal-title":"J Quant Criminol"},{"key":"10.1016\/j.jclinepi.2024.111589_bib26","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/1745691614551642","article-title":"Beyond power calculations: assessing type S (sign) and type M (magnitude) errors","volume":"9","author":"Gelman","year":"2014","journal-title":"Perspect Psychol Sci"},{"key":"10.1016\/j.jclinepi.2024.111589_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.socscimed.2017.12.005","article-title":"Understanding and misunderstanding randomized controlled trials","volume":"210","author":"Deaton","year":"2018","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.jclinepi.2024.111589_bib28","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2024.111589_bib29","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111589_bib30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrc1506","article-title":"Gefitinib\u2014a novel targeted approach to treating cancer","volume":"4","author":"Herbst","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jclinepi.2024.111589_bib31","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2015.2316","article-title":"The platform trial: an efficient strategy for evaluating multiple treatments","volume":"313","author":"Berry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2024.111589_bib32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-statistics-031017-100101","article-title":"Cure models in survival analysis","volume":"5","author":"Amico","year":"2018","journal-title":"Annu Rev Stat Appl"},{"key":"10.1016\/j.jclinepi.2024.111589_bib33","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2024.111589_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.annonc.2022.02.224","volume":"33","author":"Paz-Ares","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jclinepi.2024.111589_bib35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt Molins","year":"2021","journal-title":"Lancet Oncol 2021"},{"key":"10.1016\/j.jclinepi.2024.111589_bib36","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435624003457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435624003457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T15:31:46Z","timestamp":1741015906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435624003457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"alternative-id":["S0895435624003457"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111589","relation":{},"ISSN":["0895-4356"],"issn-type":[{"type":"print","value":"0895-4356"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statistical noise in PD-(L)1 inhibitor trials: unraveling the durable-responder effect","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111589"}}